Citations

Showing 10 of 108162 citations.

Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer
Floberg, John M. , Zhang, Jin , DeWees, T.A. , Inkman, Matthew , Chen, Kevin , Lin, Alexander J. , Rashmi, Ramachandran , Jayachandran, Kay , Edelson, Brian T. , Siegel, Barry A. , Dehdashti, Farrokh , Grigsby, Perry W. , Schwarz, Julie K. , DeWees, Todd A , Inkman, Matthew , Lin, Alexander J , Jayachandran, Kay , Siegel, Barry A , Dehdashti, Farrokh , Grigsby, Perry W , Schwarz, Julie K , Muhammad, Naoshad , Markovina, Stephanie T.

Mayo Clinic

Clinical Cancer Research | April 5, 2021 | Volume: 27 | Issue: 15 | Pages: 4245-4255

10.1158/1078-0432.ccr-20-4450 | PMID 33820781 Get It

Abstract Purpose: Chemoradiotherapy for locally advanced cervical cancer fails in over a third of patients. Biomarkers with therapeutic implications are therefore needed. We investigated the relationship between an established prognostic marker, maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography, and the inflammatory and immune state of cervical cancers. Experimental Design: An SUVmax most prognostic for freedom from progression (FFP) was identified and compared with known prognostic clinical variables in a cohort of 318 patients treated with definitive radiation with prospectively collected clinical data. Gene set enrichment analysis (GSEA) and CIBERSORT of whole-transcriptome data from 68 patients were used to identify biological pathways and immune cell subpopulations associated with high SUVmax. IHC using a tissue microarray (TMA, N = 82) was used to validate the CIBERSORT findings. The impact of macrophages on cervical cancer glucose metabolism was investigated in coculture experiments. Results: SUVmax <11.4 was most prognostic for FFP (P = 0.001). The GSEA showed that high SUVmax is associated with increased gene expression of inflammatory pathways, including JAK/STAT3 signaling. CIBERSORT and CD68 staining of the TMA showed high SUVmax tumors are characterized by a monocyte-predominant immune infiltrate. Coculture of cervical cancer cells with macrophages or macrophage-conditioned media altered glucose uptake, and IL6 and JAK/STAT3 signaling contribute to this effect. Conclusions: SUVmax is a prognostic marker in cervical cancer that is associated with activation of inflammatory pathways and tumor infiltration of myeloid-derived immune cells, particularly macrophages. Macrophages contribute to changes in cervical cancer glucose metabolism. See related commentary by Williamson et al., p. 4136
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Shafique, Michael , Fisher, Terrence L. , Evans, Elizabeth E. , Leonard, John E. , Pastore, Desa Rae E. , Mallow, Crystal, Smith, Ernest, Mishra, Vikas , Schröder, Andreas , Chin, Kevin M. , Baumgart, Megan , Govindan, Ramaswamy , Gabrail, Nashat , Lou, Yanyan , Zauderer, Maurice , Shafique, Michael R , Beck, Joseph T , Baumgart, Megan A , Seetharamu, Nagashree , Mansfield, Aaron S , Sanborn, Rachel E , Goldman, Jonathan W , Govindan, Ramaswamy , Beck, J. Thaddeus , Spira, Alexander I. , Mansfield, Aaron S. , Goldman, Jonathan W.

Mayo Clinic

Clinical Cancer Research | April 5, 2021 | Volume: 27 | Issue: 13 | Pages: 3630-3640

10.1158/1078-0432.ccr-20-4792 | PMID 33820783 Get It

Abstract Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune suppression via pepinemab with sustained T-cell activation via checkpoint inhibition. Patients and Methods: This phase Ib/II, single-arm study was designed to evaluate the safety, tolerability, and efficacy of pepinemab in combination with avelumab in 62 patients with advanced non–small cell lung cancer (NSCLC), including immunotherapy-naïve (ION) patients and patients whose tumors progressed following anti-PD-1/L1 monotherapy (IOF). The main objectives were to evaluate safety/tolerability, establish a recommended phase 2 dose (RP2D), obtain a preliminary evaluation of antitumor activity, and investigate candidate biomarker activity. Results: The combination was well tolerated with no major safety signals identified. Pepinemab, 10 mg/kg with avelumab, 10 mg/kg, every 2 weeks, was selected as the RP2D. Among 21 evaluable ION patients, 5 patients experienced partial responses (PR), 4 patients evidenced clinical benefit ≥1 year, and the disease control rate (DCR) was 81%. Notably, overall response rate with the combination therapy was higher than previously reported for single-agent avelumab in the PD-L1-negative/low population. Among 29 evaluable IOF patients, the combination resulted in a DCR of 59%, including 2 PR and 7 patients with durable clinical benefit of ≥23 weeks. Biomarker analysis of biopsies demonstrated increased CD8 T-cell density correlating with RECIST response criteria. Conclusions: The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy-resistant and PD-L1-negative/low tumors.
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Lim, Bora , Potter, David A. , Silverman, Paula , Haddad, Tufia C. , Forget, Frédéric, Awada, Ahmad , Canon, Jean‐Luc, Danso, Michael A., Lortholary, Alain , Bourgeois, Hugues , Tan-Chiu, Elizabeth, Vincent, Sylvie , Bahamón, Brittany, Neuwirth, Rachel, Leonard, E. Jane , Diamond, Jennifer R. , Silverman, Paula , Haddad, Tufia C , Awada, Ahmad , Bourgeois, Hugues , Vincent, Sylvie , Galinsky, Kevin J , Potter, David A , Salkeni, Mohamad Adham , Canon, Jean-Luc Re , Patel, Chirag Amrutlal , Lim, Bora

Mayo Clinic

Clinical Cancer Research | April 5, 2021 | Volume: 27 | Issue: 12 | Pages: 3329-3338

10.1158/1078-0432.ccr-20-4131 | PMID 33820779 Get It

Abstract Purpose: This open-label, multicenter, phase IB/II study evaluated sapanisertib, a dual inhibitor of mTOR kinase complexes 1/2, plus exemestane or fulvestrant in postmenopausal women with hormone receptor–positive (HR+)/HER2-negative (HER2−) advanced/metastatic breast cancer. Patients and Methods: Eligible patients had previously progressed on everolimus with exemestane/fulvestrant and received ≤3 (phase IB) or ≤1 (phase II) prior chemotherapy regimens. Patients received sapanisertib 3 to 5 mg every day (phase IB), or 4 mg every day (phase II) with exemestane 25 mg every day or fulvestrant 500 mg monthly in 28-day cycles. Phase II enrolled parallel cohorts based on prior response to everolimus. The primary objective of phase II was to evaluate antitumor activity by clinical benefit rate at 16 weeks (CBR-16). Results: Overall, 118 patients enrolled in phase IB (n = 24) and II (n = 94). Five patients in phase IB experienced dose-limiting toxicities, at sapanisertib doses of 5 mg every day (n = 4) and 4 mg every day (n = 1); sapanisertib 4 mg every day was the MTD in combination with exemestane or fulvestrant. In phase II, in everolimus-sensitive versus everolimus-resistant cohorts, CBR-16 was 45% versus 23%, and overall response rate was 8% versus 2%, respectively. The most common adverse events were nausea (52%), fatigue (47%), diarrhea (37%), and hyperglycemia (33%); rash occurred in 17% of patients. Molecular analysis suggested positive association between AKT1 mutation status and best treatment response (complete + partial response; P = 0.0262). Conclusions: Sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit in postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer.
Interrater agreement for sonographic stomach position classification in fetal diaphragmatic hernia across the North American Fetal Therapy Network
Abbasi, Nimrah , Ruano, Rodrigo , Ye, Xiang Y. , Shah, Prakesh S. , Filly, Roy A., Benachi, Alexandra , Johnson, Anthony , NAFTNet, Papanna, Ramesha , Ruano, Rodrigo , Cortes, Magda Sanz , Benachi, Alexandra , Ryan, Greg , NAFTNet, Papanna, Ramesha

Mayo Clinic

Prenatal Diagnosis | April 5, 2021 | Volume: 42 | Issue: 3 | Pages: 348-356

10.1002/pd.5949 | PMID 33817814 Get It

AbstractObjectiveTo evaluate inter‐rater agreement for sonographic classification of stomach position (as a surrogate for liver herniation) in fetal left congenital diaphragmatic hernia (LCDH) among: (i) fetal medicine specialists from the North American Fetal Therapy Network (NAFTNet) centers within and without the fetal endoscopic tracheal occlusion (FETO) consortium and in comparison to an expert external reviewer (ER1); and (iii) among two expert ERs (ER1 and ER2).MethodsForty‐eight physicians from 26 NAFTNet centers and 2 ERs were asked to assess 13 sonographic clips of isolated LCDH and classify stomach position as “intra‐abdominal,” “anterior left chest,” “mid to posterior left chest,” or “retro‐cardiac" based on the classification published by Basta et al.8 Interrater agreement was assessed by determining proportion of stomach position ratings concordant amongst NAFTNet participants and ER1. Agreement for stomach position between ERs was calculated using kappa statistics.ResultsAgreement for stomach position was 69% (39%–85%; n = 19) and 54% (23%–92%; n = 29) among FETO and non‐FETO NAFTNet participants, respectively, when compared to ER1. Most disagreement in stomach position was related to a discrepancy of one position. ERs were in agreement for stomach position in 5 of 13 cases (38.5%) and inter‐rater agreement was highest for “anterior” stomach position.ConclusionInterrater agreement for stomach position assessment in CDH was poor across NAFTNet and indeed amongst expert reviewers.
Ewing sarcoma
Eaton, Bree R. , Claude, L. , Indelicato, Daniel J. , Vatner, Ralph E. , Yeh, Brian, Schwarz, Rudolf, Laack, Nadia N. , Claude, Line , Laack, Nadia N Issa , Indelicato, Daniel J

Mayo Clinic

Pediatric Blood & Cancer | April 5, 2021 | Volume: 68 | Issue: S2 | Pages: No page available

10.1002/pbc.28355 | PMID 33818887 Get It

Abstract Ewing sarcoma is a rare tumor that requires complex multidisciplinary management. This report describes the general management and standard radiotherapy guidelines in both North America (Children's Oncology Group) and Europe (International Society of Pediatric Oncology). Standard treatment involves multiagent induction chemotherapy followed by local treatment with surgery, definitive radiation, or a combination of surgery and radiation followed by additional chemotherapy and consolidation local treatment to metastatic sites. The data supporting the role of chemotherapy, surgery, and radiation and specific radiation therapy guidelines are presented.
Respecting upper facial anatomy for treating the glabella with neuromodulators to avoid medial brow ptosis—A refined 3‐point injection technique
Cotofana, Sebastian , Pedraza, Angela P., Kaufman, Joely , Gavril, Diana L., Hernandez, Claudia A, Onishi, Emy C., Nikolis, Andreas , Sakuma, Thais Harumi , Frank, Konstantin , Nikolis, Andreas , Sakuma, Thais , Frank, Konstantin , Cotofana, Sebastian , Avelar, Luiz Eduardo Toledo

Mayo Clinic

Journal of Cosmetic Dermatology | April 5, 2021 | Volume: 20 | Issue: 6 | Pages: 1625-1633

10.1111/jocd.14133 | PMID 33817912 Get It

AbstractBackgroundCurrent injection algorithms for treating the glabella rely on a five‐ or seven‐point injection technique with possible medial eyebrow ptosis and lateral eyebrow elevation as undesirable outcomes.ObjectiveThe objective of this study was to investigate the efficacy and safety profile of a refined 3‐point injection technique targeting horizontal and vertical glabellar lines.MethodsA total of n=105 patients (27 males and 78 females) with a mean age of 40.90 ± 9.2 years were investigated. The injection technique relied on targeting the muscular origin of the procerus and the corrugator supercilii muscles exclusively. The time of effect onset and the injection‐related outcome 120 days after the treatment was evaluated using the 5‐point glabellar line severity scale.ResultsThe onset of the neuromodulator effect was on average 3.5 ± 1.5 days. There was no statistically significant difference in the amplitude of movement before or 14 days after the treatment with 2.99 ± 4.4 mm vs. 3.39 ± 3.6 mm (p = 0.149) for the medial head of the eyebrow and with 3.18 ± 4.7 mm vs. 3.33 ± 4.3 mm (p = 0.510) for the lateral head of the eyebrow, respectively.ConclusionIncorporating anatomic concepts into clinical practice for glabellar frown line neuromodulator treatments with the investigated 3‐point injection technique resulted in the absence of adverse events like eyebrow ptosis, upper eyelid ptosis, medial eyebrow ptosis, and lateral frontalis hyperactivity. This technique demonstrated efficacy throughout the 4‐month study period.
Harnessing the Chaplain’s Capacity to Identify Unmet Palliative Needs of Vulnerable Older Adults in the Emergency Department
Howard, E , Schwartz, Rachel , Feldstein, Bruce, Grudzen, Marita, Klein, Lori , Piderman, Katherine M. , Hamill Howard, Elizabeth , Schwartz, Rachel , Wang, David

Mayo Clinic

Journal of Palliative Care | April 5, 2021 | Volume: 37 | Issue: 4 | Pages: 480-485

10.1177/08258597211003359 | PMID 33818162 Get It

Objective: To explore chaplains’ ability to identify unmet palliative care (PC) needs in older emergency department (ED) patients. Methods: A palliative chaplain-fellow conducted a retrospective chart review evaluating 580 ED patients, age ≥80 using the Palliative Care and Rapid Emergency Screening (P-CaRES) tool. An emergency medicine physician and chaplain-fellow screened 10% of these charts to provide a clinical assessment. One year post-study, charts were re-examined to identify which patients received PC consultation (PCC) or died, providing an objective metric for comparing predicted needs with services received. Results: Within one year of ED presentation, 31% of the patient sub-sample received PCC; 17% died. Forty percent of deceased patients did not receive PCC. Of this 40%, chaplain screening for P-CaRES eligibility correctly identified 75% of the deceased as needing PCC. Conclusion: Establishing chaplain-led PC screenings as standard practice in the ED setting may improve end-of-life care for older patients.
Primary age‐related EBV‐associated effusion‐based lymphoma successfully treated with rituximab and thoracentesis
Kuhlman, Justin J. , Moustafa, Muhamad Alhaj , Tun, Alexander J., Menke, David M. , Jiang, Liuyan , Moustafa, Muhamad Alhaj , Tun, Han W. , Jiang, Liuyan , Kuhlman, Justin

Mayo Clinic

Clinical Case Reports | April 5, 2021 | Volume: 9 | Issue: 5 | Pages: No page available

10.1002/ccr3.3971 | PMID 34094552 Get It

AbstractEBV‐positive HHV8‐negative EBL is part of the spectrum of EBV‐positive diffuse large B‐cell lymphoma NOS. This entity can be labeled as primary age‐related EBV‐associated EBL and appears to respond well to rituximab and thoracentesis.
Dosimetric feasibility of stereotactic ablative radiotherapy in pulmonary vein isolation for atrial fibrillation using intensity‐modulated proton therapy
Ren, Xueying , He, Peng‐Kang, Gao, Xian‐Shu, Zhao, Zhi‐Lei, Zhao, Bo , Bai, Yun , Liu, Si‐Wei, Li, Kang , Qin, Shangbin, Ma, Mingwei , Zhou, Jing , Rong, Yi

Mayo Clinic

Journal of Applied Clinical Medical Physics | April 5, 2021 | Volume: 22 | Issue: 5 | Pages: 79-88

10.1002/acm2.13239 | PMID 33817981 Get It

Abstract Purpose To evaluate dosimetric properties of intensity‐modulated proton therapy (IMPT) for simulated treatment planning in patients with atrial fibrillation (AF) targeting left atrial‐pulmonary vein junction (LA‐PVJ), in comparison with volumetric‐modulated arc therapy (VMAT) and helical tomotherapy (TOMO). Methods Ten thoracic 4D‐CT scans with respiratory motion and one with cardiac motion were used for the study. Ten respiratory 4D‐CTs were planned with VMAT, TOMO, and IMPT for simulated AF. Targets at the LA‐PVJ were defined as wide‐area circumferential ablation line. A single fraction of 25 Gy was prescribed to all plans. The interplay effects from cardiac motion were evaluated based on the cardiac 4D‐CT scan. Dose‐volume histograms (DVHs) of the ITV and normal tissues were compared. Statistical analysis was evaluated via one‐way Repeated‐Measures ANOVA and Friedman’s test with Bonferroni’s multiple comparisons test. Results The median volume of ITV was 8.72cc. All plans had adequate target coverage (V 23.75Gy ≥ 99%). Compared with VMAT and TOMO, IMPT resulted in significantly lower dose of most normal tissues. For VMAT, TOMO, and IMPT plans, D mean of the whole heart was 5.52 ± 0.90 Gy, 5.89 ± 0.78 Gy, and 3.01 ± 0.57 Gy ( P < 0.001), mean dose of pericardium was 4.74 ± 0.76 Gy, 4.98 ± 0.62 Gy, and 2.59 ± 0.44 Gy ( P < 0.001), and D 0.03cc of left circumflex artery (LCX) was 13.96 ± 5.45 Gy, 14.34 ± 5.91 Gy, and 8.43 ± 7.24 Gy ( P < 0.001), respectively. However, no significant advantage for one technique over the others was observed when examining the D 0.03cc of esophagus and main bronchi. Conclusions IMPT targeting LA‐PVJ for patients with AF has high potential to reduce dose to surrounding tissues compared to VMAT or TOMO. Motion mitigation techniques are critical for a particle‐therapy approach.
The Range of Cardiogenic Shock Survival by Clinical Stage: Data From the Critical Care Cardiology Trials Network Registry
Lawler, Patrick R. , Berg, David D. , Park, Jeong‐Gun , Katz, Jason N. , Baird-Zars, Vivian M., Barsness, Gregory W. , Bohula, Erin A. , Menon, Venu , Metkus, Thomas S. , Nativi-Nicolau, José , Phreaner, Nicholas , Teuteberg, Jeffrey J. , Lawler, Patrick , Bohula, Erin A , Berg, David , Carnicelli, Anthony , Chaudhry, Sunit‐Preet , Jentzer, Jacob C. , Sinha, Shashank S , Diepen, Sean van , Morrow, David A.

Mayo Clinic

Critical Care Medicine | April 4, 2021 | Volume: 49 | Issue: 8 | Pages: 1293-1302

10.1097/ccm.0000000000004948 | PMID 33861557 Get It

OBJECTIVES: Cardiogenic shock presents with variable severity. Categorizing cardiogenic shock into clinical stages may improve risk stratification and patient selection for therapies. We sought to determine whether a structured implementation of the 2019 Society for Cardiovascular Angiography and Interventions clinical cardiogenic shock staging criteria that is ascertainable in clinical registries discriminates mortality in a contemporary population with or at-risk for cardiogenic shock. DESIGN: We developed a pragmatic application of the Society for Cardiovascular Angiography and Interventions cardiogenic shock staging criteria—A (at-risk), B (beginning), C (classic cardiogenic shock), D (deteriorating), or E (extremis)—and examined outcomes by stage. SETTING: The Critical Care Cardiology Trials Network is an investigator-initiated multicenter research collaboration coordinated by the TIMI Study Group (Boston, MA). Consecutive admissions with or at-risk for cardiogenic shock during two annual 2-month collection periods (2017–2019) were analyzed. PATIENTS: Patients with or at-risk for cardiogenic shock. MEASUREMENTS AND MAIN RESULTS: Of 8,240 CICU admissions reviewed, 1,991 (24%) had or were at-risk for cardiogenic shock. Distributions across the five stages were as follows: A: 33%; B: 7%; C: 16%; D: 23%; and E: 21%. Overall in-hospital mortality among patients with established cardiogenic shock was 39%; however, mortality varied from only 15.8% to 32.1% to 62.5% across stages C, D, and E (Cochran-Armitage p trend < 0.0001). The Society for Cardiovascular Angiography and Interventions stages improved mortality prediction beyond the Sequential Organ Failure Assessment and Intra-Aortic Balloon Pumpin Cardiogenic Shock II scores. CONCLUSIONS: Although overall mortality in cardiogenic shock remains high, it varies considerably based on clinical stage, identifying stage C as relatively lower risk. We demonstrate a pragmatic adaptation of the Society for Cardiovascular Angiography and Interventions cardiogenic shock stages that effectively stratifies mortality risk and could be leveraged for future clinical research.